Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest

Area of Science:

• Oncology
• Immunology
• Cancer Biology

Background:

• Targeted oncogene inhibition and immunotherapy are effective against metastatic cancer but often yield limited or transient responses.
• Mechanisms underlying the synergistic cooperation between oncogene inhibitors and immunotherapy remain incompletely understood.
• The BRAF(V600E) mutation is a key driver in certain metastatic cancers, representing a target for therapy.

Purpose of the Study:

• To explore potential synergistic mechanisms between the BRAF(V600E) inhibitor vemurafenib and adoptive cell transfer (ACT) immunotherapy.
• To investigate how combining these therapies impacts tumor progression and immune cell function in a BRAF(V600E)-mutant melanoma model.
• To elucidate the molecular basis for any observed synergy between vemurafenib and ACT.

Main Methods:

• Utilized a novel transplantable BRAF(V600E)-mutant murine melanoma model (SB-3123).
• Administered vemurafenib (BRAF inhibitor) in combination with ACT-based immunotherapy.
• Assessed tumor progression, CD8(+) T cell infiltration and function, and tumor cell proliferation in vitro and in vivo.
• Performed molecular profiling of treated tumors.
• Tested combinatorial effects in human melanoma-derived cell lines.

Main Results:

• Vemurafenib and ACT cooperated to delay melanoma progression.
• This combination did not significantly alter tumor infiltration or effector function of CD8(+) T cells.
• T-cell cytokines IFNγ and TNFα synergized with vemurafenib to induce tumor cell-cycle arrest in vitro.
• This synergistic effect was observed in human BRAF(V600E)-mutant melanoma cell lines.
• Vemurafenib sensitized tumor cells to the antiproliferative effects of T-cell cytokines.

Conclusions:

• The combination of vemurafenib and ACT demonstrates synergy in delaying melanoma progression.
• Synergy is mediated by T-cell cytokines (IFNγ, TNFα) inducing cell-cycle arrest in BRAF(V600E)-mutant cancer cells when combined with vemurafenib.
• This finding highlights the interplay between oncogenic signaling and immune responses.
• Provides a rationale for developing combinatorial therapies targeting both oncogene drivers and immune signaling in metastatic cancers.